Shanghai RAAS Blood Products Co., Ltd. (SHE: 002252)
China
· Delayed Price · Currency is CNY 7.57
+0.03 (0.40%)
Nov 15, 2024, 10:31 AM CST
Shanghai RAAS Blood Products Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 8,341 | 7,962 | 6,566 | 4,285 | 2,761 | 2,585 | Upgrade
|
| Other Revenue | 1.57 | 1.57 | 1.32 | 3.01 | 0.99 | 0.23 | Upgrade
|
| Revenue | 8,343 | 7,964 | 6,567 | 4,288 | 2,762 | 2,585 | Upgrade
|
| Revenue Growth (YoY) | 10.49% | 21.27% | 53.16% | 55.26% | 6.84% | 43.27% | Upgrade
|
| Cost of Revenue | 5,036 | 4,735 | 3,678 | 2,069 | 1,059 | 935.99 | Upgrade
|
| Gross Profit | 3,307 | 3,229 | 2,889 | 2,219 | 1,702 | 1,649 | Upgrade
|
| Selling, General & Admin | 743.34 | 712.75 | 706.48 | 616.64 | 528.98 | 632.84 | Upgrade
|
| Research & Development | 232.06 | 173.74 | 145.71 | 129.02 | 129.69 | 102.44 | Upgrade
|
| Other Operating Expenses | 49.72 | 31.52 | 32.81 | 23.05 | 20.36 | 18.65 | Upgrade
|
| Operating Expenses | 1,051 | 912.7 | 900.18 | 756.75 | 682.58 | 752.93 | Upgrade
|
| Operating Income | 2,256 | 2,316 | 1,989 | 1,462 | 1,020 | 896.06 | Upgrade
|
| Interest Expense | -0.1 | -0.12 | -0.26 | -0.47 | -0.38 | -1.69 | Upgrade
|
| Interest & Investment Income | 265.26 | 135.38 | 510.69 | 466.09 | 599.35 | 42.93 | Upgrade
|
| Currency Exchange Gain (Loss) | -43.34 | -43.34 | -56.55 | 11.28 | -9.95 | 1.17 | Upgrade
|
| Other Non Operating Income (Expenses) | 32.47 | -0.42 | -1.42 | -1.91 | -0.69 | -58.19 | Upgrade
|
| EBT Excluding Unusual Items | 2,510 | 2,408 | 2,441 | 1,937 | 1,608 | 880.28 | Upgrade
|
| Impairment of Goodwill | - | - | -197.02 | -361.19 | -129.68 | -143.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | -173.31 | -196.89 | 18.38 | -42.76 | -17.58 | -31.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.62 | -0.01 | 0.23 | -1.35 | 0.97 | 4.07 | Upgrade
|
| Asset Writedown | -11.02 | -4.43 | -2.47 | -9.26 | -2.79 | -0.77 | Upgrade
|
| Other Unusual Items | -63.94 | -2.37 | 13.11 | 16.54 | 18.35 | 24.51 | Upgrade
|
| Pretax Income | 2,260 | 2,204 | 2,274 | 1,539 | 1,477 | 733.14 | Upgrade
|
| Income Tax Expense | 430.12 | 426.65 | 400.61 | 250.09 | 158.64 | 127.22 | Upgrade
|
| Earnings From Continuing Operations | 1,830 | 1,777 | 1,873 | 1,289 | 1,319 | 605.92 | Upgrade
|
| Minority Interest in Earnings | -0.65 | 2.04 | 7.09 | 5.56 | 5.12 | 1.97 | Upgrade
|
| Net Income | 1,830 | 1,779 | 1,880 | 1,295 | 1,324 | 607.89 | Upgrade
|
| Net Income to Common | 1,830 | 1,779 | 1,880 | 1,295 | 1,324 | 607.89 | Upgrade
|
| Net Income Growth | -11.35% | -5.35% | 45.24% | -2.21% | 117.75% | - | Upgrade
|
| Shares Outstanding (Basic) | 6,628 | 6,692 | 6,741 | 6,741 | 6,403 | 5,066 | Upgrade
|
| Shares Outstanding (Diluted) | 6,629 | 6,693 | 6,741 | 6,741 | 6,403 | 5,066 | Upgrade
|
| Shares Change (YoY) | -1.45% | -0.70% | - | 5.28% | 26.40% | 3.42% | Upgrade
|
| EPS (Basic) | 0.28 | 0.27 | 0.28 | 0.19 | 0.21 | 0.12 | Upgrade
|
| EPS (Diluted) | 0.28 | 0.27 | 0.28 | 0.19 | 0.21 | 0.12 | Upgrade
|
| EPS Growth | -10.02% | -4.66% | 46.80% | -8.09% | 72.28% | - | Upgrade
|
| Free Cash Flow | 445.21 | 1,827 | 1,500 | 1,089 | 917.09 | 717.82 | Upgrade
|
| Free Cash Flow Per Share | 0.07 | 0.27 | 0.22 | 0.16 | 0.14 | 0.14 | Upgrade
|
| Dividend Per Share | 0.067 | 0.030 | 0.030 | 0.028 | 0.025 | 0.010 | Upgrade
|
| Dividend Growth | 123.33% | 0% | 7.14% | 12.00% | 150.00% | - | Upgrade
|
| Gross Margin | 39.64% | 40.55% | 43.99% | 51.75% | 61.64% | 63.79% | Upgrade
|
| Operating Margin | 27.04% | 29.08% | 30.29% | 34.10% | 36.92% | 34.66% | Upgrade
|
| Profit Margin | 21.93% | 22.34% | 28.63% | 30.19% | 47.93% | 23.52% | Upgrade
|
| Free Cash Flow Margin | 5.34% | 22.94% | 22.84% | 25.41% | 33.21% | 27.77% | Upgrade
|
| EBITDA | 2,394 | 2,473 | 2,169 | 1,616 | 1,172 | 1,045 | Upgrade
|
| EBITDA Margin | 28.70% | 31.05% | 33.03% | 37.69% | 42.45% | 40.41% | Upgrade
|
| D&A For EBITDA | 138.41 | 156.38 | 180.33 | 154.07 | 152.76 | 148.46 | Upgrade
|
| EBIT | 2,256 | 2,316 | 1,989 | 1,462 | 1,020 | 896.06 | Upgrade
|
| EBIT Margin | 27.04% | 29.08% | 30.29% | 34.10% | 36.92% | 34.66% | Upgrade
|
| Effective Tax Rate | 19.03% | 19.36% | 17.62% | 16.25% | 10.74% | 17.35% | Upgrade
|
| Revenue as Reported | 8,343 | 7,964 | 6,567 | 4,288 | 2,762 | 2,585 | Upgrade
|
| Advertising Expenses | - | 142.52 | 193.23 | 169.52 | 98.94 | 139.03 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.